JP2017513937A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513937A5
JP2017513937A5 JP2017504289A JP2017504289A JP2017513937A5 JP 2017513937 A5 JP2017513937 A5 JP 2017513937A5 JP 2017504289 A JP2017504289 A JP 2017504289A JP 2017504289 A JP2017504289 A JP 2017504289A JP 2017513937 A5 JP2017513937 A5 JP 2017513937A5
Authority
JP
Japan
Prior art keywords
seq
air marker
patient
antagonist
air
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017504289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/052551 external-priority patent/WO2015155710A1/en
Publication of JP2017513937A publication Critical patent/JP2017513937A/ja
Publication of JP2017513937A5 publication Critical patent/JP2017513937A5/ja
Ceased legal-status Critical Current

Links

JP2017504289A 2014-04-11 2015-04-08 Il−13アンアゴニストを用いて喘息を選択的に治療する方法 Ceased JP2017513937A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978604P 2014-04-11 2014-04-11
US61/978,604 2014-04-11
PCT/IB2015/052551 WO2015155710A1 (en) 2014-04-11 2015-04-08 Methods of selectively treating asthma using il-13 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019229495A Division JP2020079241A (ja) 2014-04-11 2019-12-19 Il−13アンアゴニストを用いて喘息を選択的に治療する方法

Publications (2)

Publication Number Publication Date
JP2017513937A JP2017513937A (ja) 2017-06-01
JP2017513937A5 true JP2017513937A5 (enExample) 2018-04-26

Family

ID=52997487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017504289A Ceased JP2017513937A (ja) 2014-04-11 2015-04-08 Il−13アンアゴニストを用いて喘息を選択的に治療する方法
JP2019229495A Pending JP2020079241A (ja) 2014-04-11 2019-12-19 Il−13アンアゴニストを用いて喘息を選択的に治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019229495A Pending JP2020079241A (ja) 2014-04-11 2019-12-19 Il−13アンアゴニストを用いて喘息を選択的に治療する方法

Country Status (12)

Country Link
US (2) US10066267B2 (enExample)
EP (1) EP3129497B1 (enExample)
JP (2) JP2017513937A (enExample)
KR (1) KR20160138095A (enExample)
CN (1) CN106536754B (enExample)
AU (2) AU2015246037B2 (enExample)
BR (1) BR112016023238A2 (enExample)
CA (1) CA2943326A1 (enExample)
MX (1) MX2016013372A (enExample)
RU (1) RU2694980C2 (enExample)
TW (1) TW201542227A (enExample)
WO (1) WO2015155710A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11312956B2 (en) 2016-07-08 2022-04-26 Tak-Circulator Co., Ltd Nucleic acid inhibiting expression of the MEX3B gene, MEX3B gene expression inhibitor, method for inhibiting MEX3B gene expression, and prophylactic or therapeutic agent for disease caused by MEX3B gene expression
ES3041629T3 (en) * 2016-07-08 2025-11-13 Tak Circulator Corp Method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5
JP7321939B2 (ja) * 2017-04-13 2023-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
US10650928B1 (en) * 2017-12-18 2020-05-12 Clarify Health Solutions, Inc. Computer network architecture for a pipeline of models for healthcare outcomes with machine learning and artificial intelligence
US10811139B1 (en) 2018-06-13 2020-10-20 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and dynamic patient guidance
US11763950B1 (en) * 2018-08-16 2023-09-19 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and patient risk scoring
US11625789B1 (en) 2019-04-02 2023-04-11 Clarify Health Solutions, Inc. Computer network architecture with automated claims completion, machine learning and artificial intelligence
US11621085B1 (en) 2019-04-18 2023-04-04 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and active updates of outcomes
US11238469B1 (en) 2019-05-06 2022-02-01 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and risk adjusted performance ranking of healthcare providers
US10726359B1 (en) 2019-08-06 2020-07-28 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and automated scalable regularization
US10643751B1 (en) 2019-09-26 2020-05-05 Clarify Health Solutions, Inc. Computer network architecture with benchmark automation, machine learning and artificial intelligence for measurement factors
US10643749B1 (en) 2019-09-30 2020-05-05 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and automated insight generation
US11270785B1 (en) * 2019-11-27 2022-03-08 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and care groupings
CN113215245A (zh) * 2021-05-21 2021-08-06 广州合一生物科技有限公司 一种用于儿童哮喘个体化用药的基因检测试剂盒及其应用
WO2023069116A1 (en) * 2021-10-22 2023-04-27 Illumina, Inc. Genotyping methods and systems
US12079230B1 (en) 2024-01-31 2024-09-03 Clarify Health Solutions, Inc. Computer network architecture and method for predictive analysis using lookup tables as prediction models

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6468528B1 (en) 1999-02-01 2002-10-22 Amgen Canada Inc. Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
US6645486B1 (en) 2000-01-25 2003-11-11 Ludwig Institute For Cancer Research Method of treatment with IL-9 conjugate
AU2002320630A1 (en) 2001-07-17 2003-03-03 University Of Florida Detecting and treating reproductive tract disorders
US20030143199A1 (en) 2001-10-09 2003-07-31 Carson Dennis A. Use of STAT-6 inhibitors as therapeutic agents
WO2003034984A2 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
EP1578912A4 (en) 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2004082362A2 (en) 2003-03-18 2004-09-30 Nitto Denko Corporation Methods for extending amorphous photorefractive material lifetimes
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP4943161B2 (ja) * 2003-12-23 2012-05-30 ジェネンテック, インコーポレイテッド 新規抗il13モノクローナル抗体での癌の処置
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Il−13に対する完全ヒトモノクローナル抗体
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
PL1942939T5 (pl) 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
US7910708B2 (en) * 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
TW200804593A (en) 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
US20100136030A1 (en) 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2011156000A2 (en) 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
CN103328506A (zh) 2010-10-15 2013-09-25 米迪缪尼有限公司 用于改善肺功能的疗法
EP2652498B1 (en) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition

Similar Documents

Publication Publication Date Title
RU2016144177A (ru) Способы избирательного лечения астмы с использованием антагонистов il-13
KR101719376B1 (ko) 연령-관련 황반 변성에서 유전자 다형성
JP5727484B2 (ja) I型インターフェロン診断法
AU2012341081B2 (en) Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
JP5411129B2 (ja) インターフェロンα誘導性薬力学的マーカー
JP2013518590A (ja) TNF−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
JP2015504430A5 (enExample)
JP2022046486A (ja) 眼障害を治療する方法
JP2017507130A5 (enExample)
US10617757B2 (en) Methods for treating multiple myeloma
CA2938731A1 (en) Methods of treating alzheimer's disease
KR20090088931A (ko) 인터페론 알파 유도성 약력학적 마커
JP5676623B2 (ja) 加齢黄斑変性における遺伝的多型性
RU2014146594A (ru) Способы лечения анкилозирующего спондилита с использованием антагонистов il-17
JP2017519498A5 (enExample)
WO2014155278A2 (en) Methods of treating autoimmune diseases using il-17 antagonists
JP2020531439A (ja) アトピー性皮膚炎の治療及び治療選択のための組成物及び方法
US10761098B2 (en) Methods and tools for Vel blood group typing
WO2008124937A1 (en) Alleles and polymorphisms predictive of responsiveness to biologic therapy in psoriasis
WO2002079503A1 (en) An allele of apolipoprotein e linked to neuropsychiatric disorders
JP2022515226A5 (enExample)
HK1230521B (zh) 用於诊断和治疗炎症性肠病的方法